Lower risk of hematological toxicity

Lower risk of hematological toxicity

Haematological toxicity presents a potentially life-threatening reduction in blood and bone marrow cells, elevating the likelihood of infection, anaemia, bleeding, and other adverse consequences. Various medications can induce haematological toxicity, with cancer...
Other possibilities for improved outcomes

Other possibilities for improved outcomes

Frequently, individuals discontinue their medication either because they believe it is ineffective or due to an inability to endure its side effects. It is reasonable for patients to anticipate positive results from their medications and manageable side effects....
Lower risk of cardiovascular events

Lower risk of cardiovascular events

Numerous drugs are associated with adverse cardiovascular events. Even nonsteroidal anti-inflammatory medications, generally well-tolerated in most patients, can lead to cardiovascular issues. Cardiovascular disease stands as the primary cause of death for most groups...
Antidepressant efficacy

Antidepressant efficacy

Depression stands as the primary global cause of disability, affecting 18.1 percent of the American adult population, which translates to 40 million individuals annually. The Centre for Workplace Mental Health estimates that major depressive disorder imposes a yearly...
Enhancing Patient Outcomes

Enhancing Patient Outcomes

Despite strong evidence indicating that pharmacogenomics can enhance healthcare delivery and patient results, healthcare systems in the UK have been slow to embrace genetic testing. A study conducted in 2016 suggests that a lack of awareness regarding the benefits of...
An overview of Pharmacogenomic testing

An overview of Pharmacogenomic testing

A study conducted in 2017 revealed that four out of five patients possess at least one genetic variation that could impact the effectiveness of commonly prescribed medications. While these individual genetic variations are uncommon and may not be evident in clinical...